BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 45 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,427 | -96.4% | 97,088 | -40.3% | 0.00% | -100.0% |
| Q1 2023 | $537,085 | +1828.9% | 162,753 | +858.6% | 0.00% | – |
| Q4 2022 | $27,844 | -58.4% | 16,978 | -29.7% | 0.00% | – |
| Q2 2022 | $67,000 | -59.4% | 24,134 | -50.8% | 0.00% | – |
| Q1 2022 | $165,000 | -35.3% | 49,097 | -26.2% | 0.00% | – |
| Q1 2021 | $255,000 | -45.6% | 66,512 | -35.9% | 0.00% | -100.0% |
| Q4 2020 | $469,000 | +143.0% | 103,738 | +130.2% | 0.00% | 0.0% |
| Q4 2019 | $193,000 | -60.9% | 45,059 | -64.4% | 0.00% | -75.0% |
| Q3 2019 | $493,000 | +12.3% | 126,459 | +13.7% | 0.00% | 0.0% |
| Q2 2019 | $439,000 | +116.3% | 111,245 | +137.6% | 0.00% | +100.0% |
| Q1 2019 | $203,000 | +463.9% | 46,823 | +365.1% | 0.00% | – |
| Q4 2018 | $36,000 | +1100.0% | 10,067 | +1577.8% | 0.00% | – |
| Q2 2017 | $3,000 | -66.7% | 600 | -72.5% | 0.00% | – |
| Q1 2017 | $9,000 | -18.2% | 2,180 | -43.9% | 0.00% | – |
| Q4 2015 | $11,000 | +22.2% | 3,883 | 0.0% | 0.00% | – |
| Q3 2015 | $9,000 | -43.8% | 3,883 | -11.4% | 0.00% | – |
| Q2 2015 | $16,000 | – | 4,383 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |